Objective: To examine the efficacy of bolus dose intravenous amiodarone for the pharmacological termination of haemodynamically-tolerated sustained monomorphic ventricular tachycardia (VT).
Design, Setting And Participants: Retrospective case series of consecutive emergency admissions with haemodynamically-tolerated sustained monomorphic VT administered bolus dose intravenous amiodarone 300 mg, according to current UK advanced life support practice guidelines.
Main Outcome Measures: Pharmacological termination rates within 20 min and 1 h and incidence of hypotension requiring emergency direct current cardioversion (DCCV) during this period.
Results: 41 patients (35 men) of mean (SD) age 68 (10) years, the majority (85%) with ischaemic heart disease and impaired left ventricular function (mean (SD) ejection fraction 0.31 (0.11)), were enrolled in the study. The median VT duration was 70 min (range 15-6000), mean heart rate was 174 (34) bpm and systolic and diastolic blood pressures were 112 (22) and 73 (19) mm Hg, respectively. Pharmacological VT termination occurred within 20 min in 6/41 patients (15%; 95% CI 7% to 29%) and within 1 h in 12/41 patients (29%; 95% CI 18% to 45%). Haemodynamic deterioration requiring emergency DCCV occurred in 7/41 patients (17%; 95% CI 8% to 32%).
Conclusions: Although advocated by advanced life support guidelines, bolus dose intravenous amiodarone was relatively ineffective for acutely terminating haemodynamically-tolerated sustained monomorphic VT with a significant incidence of haemodynamic destabilisation requiring emergency DCCV. Previous studies in the identical clinical setting suggest that alternative antiarrhythmic agents, particularly intravenous procainamide and sotalol, may be superior. A prospective randomised trial is required to determine the optimal drug treatment for stable sustained monomorphic VT in the emergency setting.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/emj.2007.051086 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical Profile and Management of Wolf-Parkinson White Syndrome and Asymptomatic Pre-Excitation Carriers in Africa: A Multicenter Pan African Registry From 17 Countries.
J Cardiovasc Electrophysiol
January 2025
Douala Gyneco-obstetric and Pediatric Hospital/University of Douala, Douala, Cameroon.
Article Synopsis
- The study explores the management and diagnosis of Wolf-Parkinson White Syndrome (WPW) and asymptomatic pre-excitation in Africa, highlighting a lack of data in the region.
- Conducted in 20 centers across 17 African countries, the research involved 541 participants and focused on symptomatology, treatment approaches, and the impact of local health dynamics on care.
- Results indicated that a vast majority were diagnosed with WPW, with significant regional differences in treatment options and effectiveness, showing that Northern and Southern Africa have more advanced practices compared to other areas.
Is the topical application of sesame oil (Sesamum indicum L.) combined with standard care valuable and safe for managing infusion-related phlebitis: Evidence from a systematic review with meta-analysis of randomized controlled trials.
Complement Ther Med
December 2024
Department of Operating Room Nursing, Abadan University of Medical Sciences, Abadan, Iran. Electronic address:
Article Synopsis
- The review analyzed randomized controlled trials (RCTs) to evaluate the effectiveness of topical sesame oil (SO) in preventing and managing infusion-related phlebitis (IRP), revealing inconsistent results in prior studies.
- Eight studies, covering various patients with chemotherapy and amiodarone-induced phlebitis, showed that combining standard care with SO significantly reduced IRP symptoms compared to control treatments.
- While the findings suggest that SO may positively impact IRP management, the quality of the evidence was moderate and highlighted the need for better study design and safety verification of sesame oil.
Efficacy and Safety of Amiodarone and Propranolol in Pediatric Cardiology for Arrhythmia After Cardiac Surgery: A Retrospective Design Study.
Cureus
November 2024
Cardiac Surgery, Jordanian Royal Medical Services, Amman, JOR.
Objectives The study evaluated the efficacy of antiarrhythmic pharmacotherapies in managing tachyarrhythmia episodes in pediatric patients with congenital heart diseases post-tricuspid valve repair, assessing reductions in haemodynamic parameters and symptomatic variables, and observing side effects. Methods From January 2020 to January 2024, this study reviewed data from 300 patients, aged up to 18 years, who experienced arrhythmia following cardiac surgery and received treatment with amiodarone, propranolol, or both. The information included demographic and anthropometric measures, haemodynamic parameters, and antiarrhythmic drugs used to treat arrhythmias before and after tricuspid valve repair.
View Article and Find Full Text PDFEarly recognition and prompt intervention are crucial in managing aconite poisoning. Rapid treatment with intravenous magnesium sulfate and amiodarone can stabilize severe cardiac arrhythmias. Vigilant monitoring and tailored therapeutic strategies enhance recovery and improve patient outcomes in acute poisoning cases.
View Article and Find Full Text PDFGuide Wire Stimulation During Catheter Ablation for Atrial Fibrillation-Induced Cardiac Arrest in a Patient With Preexisting Left Bundle Branch Block: A Case Report.
Cureus
October 2024
Department of Cardiology and Nephrology, Mie University Graduate School of Medicine, Tsu, JPN.
Right bundle branch block can occasionally occur when a guide wire or catheter is inserted into the heart. An 83-year-old woman with preexisting left bundle branch block (LBBB) was diagnosed with paroxysmal atrial fibrillation (PAF) and severe mitral regurgitation (MR). The patient was started on amiodarone (100 mg/day) and bisoprolol (1.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!